Cambridge Investment Research Advisors Inc. Reduces Stock Position in Bruker Co. (NASDAQ:BRKR)

Cambridge Investment Research Advisors Inc. lessened its holdings in Bruker Co. (NASDAQ:BRKR) by 5.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,035 shares of the medical research company’s stock after selling 218 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Bruker were worth $315,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. raised its position in shares of Bruker by 14.1% in the second quarter. BlackRock Inc. now owns 6,513,896 shares of the medical research company’s stock worth $494,927,000 after buying an additional 805,046 shares in the last quarter. State Street Corp raised its position in shares of Bruker by 35.9% in the second quarter. State Street Corp now owns 2,050,445 shares of the medical research company’s stock worth $155,793,000 after buying an additional 541,579 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of Bruker by 2.9% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 1,864,899 shares of the medical research company’s stock worth $141,695,000 after buying an additional 51,993 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Bruker by 3,381.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,038,827 shares of the medical research company’s stock worth $78,930,000 after buying an additional 1,008,992 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Bruker by 35.5% in the second quarter. Millennium Management LLC now owns 923,093 shares of the medical research company’s stock worth $70,137,000 after buying an additional 242,009 shares in the last quarter. Institutional investors own 68.38% of the company’s stock.

Shares of NASDAQ:BRKR opened at $70.72 on Friday. The stock’s 50-day moving average price is $79.96 and its 200-day moving average price is $81.10. Bruker Co. has a 12-month low of $54.46 and a 12-month high of $92.35. The stock has a market capitalization of $10.73 billion, a P/E ratio of 39.96, a price-to-earnings-growth ratio of 1.57 and a beta of 1.24. The company has a current ratio of 2.16, a quick ratio of 1.36 and a debt-to-equity ratio of 0.66.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, November 1st. The medical research company reported $0.63 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.19. Bruker had a return on equity of 31.48% and a net margin of 11.44%. The firm had revenue of $608.90 million for the quarter, compared to analysts’ expectations of $575.33 million. During the same period last year, the firm earned $0.42 earnings per share. The company’s revenue for the quarter was up 19.1% compared to the same quarter last year. As a group, research analysts predict that Bruker Co. will post 2.09 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 17th. Stockholders of record on Wednesday, December 1st were paid a dividend of $0.04 per share. The ex-dividend date of this dividend was Tuesday, November 30th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.23%. Bruker’s dividend payout ratio (DPR) is currently 9.04%.

A number of equities research analysts recently issued reports on BRKR shares. Wells Fargo & Company increased their price objective on Bruker from $85.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 2nd. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a research note on Tuesday, September 28th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bruker presently has an average rating of “Buy” and an average target price of $82.71.

In other news, VP Mark Munch sold 21,210 shares of the stock in a transaction dated Wednesday, December 15th. The shares were sold at an average price of $79.47, for a total transaction of $1,685,558.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Marc A. Kastner sold 10,000 shares of the stock in a transaction dated Wednesday, November 24th. The stock was sold at an average price of $76.86, for a total transaction of $768,600.00. The disclosure for this sale can be found here. 26.80% of the stock is currently owned by company insiders.

Bruker Company Profile

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST).

Featured Story: What Is an EV Stock

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.